Tubeless Insulin Pump Market size was valued at USD 11.9 billion in 2023 and is anticipated to reach USD 97.9 billion by the end of 2036, registering around 19.2% CAGR during the forecast period i.e., between 2024-2036. In 2024, the industry size of tubeless insulin pump is assessed at USD 14.1 billion.
The tubeless insulin market is driven by the rising incidence of type 1 diabetes across the globe. In 2022, a report published by the National Library of Medicine, the incidence of type 1 diabetes has drastically increased after the COVID-19 pandemic. Tubeless insulin pumps are cost-effective, user-friendly, and can be worn beneath any garment. As per a World Health Organization (WHO) report published in 2022, the world population is aging, and by 2050, 22% of the world population will be 60 years or above.
Manufacturers across the globe are focused on improving the accuracy and user-friendliness of tubeless insulin pumps to gain standard approvals for commercialization. For instance, the first automated tubeless insulin pump, Insulet’s Omnipod 5, received FDA approval in January 2022. Omnipod 5 is the first product that can be controlled via smartphone. Such ongoing groundbreaking innovations are expected to boost tubeless insulin pump market growth going ahead.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
19.2% |
|
Base Year Market Size (2023) |
USD 11.9 billion |
|
Forecast Year Market Size (2036) |
USD 97.9 billion |
|
Regional Scope |
|
Component (Patch/Pod, Remote, Accessories)
The insulin patch/pod segment in the tubeless insulin pump market accounted for the largest share and it is expected to retain its position during the forecast period. The growth of the patch pump segment can be attributed to its ease of use as it can be attached to the skin with minimal supervision for blood glucose management. Due to their user-friendly nature, they are fast replacing the traditional syringe combinations and facilitating the growth of this segment. In January 2024, Embecta Corp. announced the submission of an FDA 510 (k) for an insulin patch pump.
The remote segment is rapidly growing due to the integration of tubeless insulin pumps with smartphones. The ability to administer insulin delivery without direct contact with the device fosters better convenience for the users. The focus on convenience is boosting the growth of this segment.
End use (Hospitals, Pharmacies, e-commerce, Others)
Based on end-use, the hospitals segment had the highest tubeless insulin pump market share in 2023 owing to the rising awareness and technical insights on advanced diabetic care in hospitals and improving healthcare infrastructure. The availability of skilled healthcare professionals and a large number of hospital admissions requiring diabetic care are also expected to drive segment revenue growth during the forecast period.
Our in-depth analysis of the global tubeless insulin pump market includes the following segments:
|
Component |
|
|
Type
|
|
|
End use |
|
North America Market Statistics
North America accounted for the largest share in the tubeless insulin pump market with a 45.5% share in 2023. Product innovations, high disposable income in the population, and rising awareness of advanced diabetic care are drivers of the growth of this region. According to the Centers for Disease Centers (CDC) report (2021) 11.6% of the U.S. population was diagnosed with diabetes. The government's efforts in diabetes care is rising with frequent campaigns being conducted to raise awareness and it has boosted the adoption of tubeless insulin pumps across the country.
In Canada, 5.7 million of the population are diagnosed with type 1 or type 2 diabetes as reported by Diabetes Canada in 2022. Due to the availability of different types of tubeless insulin pumps and presence of well-established healthcare facilities in the U.S. and Canada, both countries are prominent contributors to the North America market.
Asia Pacific Market Analysis
Asia Pacific tubeless insulin pump market is expected to record significant growth between 2024-2036. Two of the countries with the highest rate of diabetes are from Asia Pacific i.e. China and India. In 2021, 140.9 million people were diagnosed with diabetes in China while 74.2 million were diagnosed in India. The increasing cases have prompted the governments to invest more in the healthcare sectors and raise initiatives for diabetes care.
The region is also accepting the influx of better technology and innovations. The rate of disposable income in the middle class of countries such as China and India are also rising which allows users to be able to afford advanced diabetic care. These are some of the key drivers that is poised to make the Asia Pacific the fastest-growing market in the tubeless insulin pump sector.
The tubeless insulin pump market is competitive and new players are emerging. Several global and regional players are competing in this sector. The sector is very innovation driven as the focus is to improve the convenience of end-users. The key players are focused on innovation, partnerships, mergers & acquisitions to increase their tubeless insulin pump market share.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?